CA2352178A1 - Compositions de phospholipides - Google Patents

Compositions de phospholipides Download PDF

Info

Publication number
CA2352178A1
CA2352178A1 CA002352178A CA2352178A CA2352178A1 CA 2352178 A1 CA2352178 A1 CA 2352178A1 CA 002352178 A CA002352178 A CA 002352178A CA 2352178 A CA2352178 A CA 2352178A CA 2352178 A1 CA2352178 A1 CA 2352178A1
Authority
CA
Canada
Prior art keywords
lipid
composition
polymer
active compound
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352178A
Other languages
English (en)
Inventor
Mathew Louis Steven Leigh
Steven Leigh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phares Pharmaceutical Research NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9827006A external-priority patent/GB2344520A/en
Priority claimed from GBGB9925365.0A external-priority patent/GB9925365D0/en
Application filed by Individual filed Critical Individual
Publication of CA2352178A1 publication Critical patent/CA2352178A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

La présente invention se rapporte à la préparation de compositions sous formes solide ou en poudre, comprenant des lipides amphiphiles à simple et double chaînes en association avec des polymères qui les durcissent, ce qui permet de les réduire sous formes de poudre ou de granules. Les compositions peuvent servir comme supports de composés biologiquement actifs et être administrées à des organismes vivants. Une telle composition peut comprendre un composé biologiquement actif et un lipide membranaire monoacyle et diacyle en association avec un polymère. Une telle composition sous forme solide, stockée dans un récipient en verre, reste pulvérulente après 3 mois à 40 ·C et à 75 % d'humidité relative. Les lipides peuvent être choisis parmi ceux qui sont reconnus généralement inoffensifs (GRAS), tels que de la lécithine modifiée enzymatiquement, et les polymères peuvent être choisis parmi des polysaccharides naturels, des amidons et leurs dérivés, la cellulose et ses dérivés, et la gélatine.
CA002352178A 1998-12-08 1999-12-08 Compositions de phospholipides Abandoned CA2352178A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9827006.9 1998-12-08
GB9827006A GB2344520A (en) 1998-12-08 1998-12-08 Pharmaceutical carriers comprising lipids and polymers
GB9925365.0 1999-10-27
GBGB9925365.0A GB9925365D0 (en) 1999-10-27 1999-10-27 Phospholipid compositions
PCT/GB1999/004070 WO2000033817A1 (fr) 1998-12-08 1999-12-08 Compositions de phospholipides

Publications (1)

Publication Number Publication Date
CA2352178A1 true CA2352178A1 (fr) 2000-06-15

Family

ID=26314804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352178A Abandoned CA2352178A1 (fr) 1998-12-08 1999-12-08 Compositions de phospholipides

Country Status (5)

Country Link
EP (1) EP1137402A1 (fr)
JP (1) JP2002532389A (fr)
AU (1) AU1787800A (fr)
CA (1) CA2352178A1 (fr)
WO (1) WO2000033817A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055820A1 (fr) 2019-09-20 2021-03-25 Novartis Ag Acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et sa formulation de sels
WO2022195545A1 (fr) 2021-03-18 2022-09-22 Novartis Ag Nouvelles formulations pharmaceutiques

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498420B1 (fr) 2002-03-29 2017-02-01 Nof Corporation Derive phospholipidique
US7531604B2 (en) 2002-09-30 2009-05-12 Nof Corporation Phospholipid derivative
JP4403303B2 (ja) 2003-01-06 2010-01-27 日油株式会社 リン脂質誘導体及びその製造方法
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
WO2004083219A1 (fr) 2003-03-20 2004-09-30 Nof Corporation Derives phospholipidiques
CN100553680C (zh) 2004-02-17 2009-10-28 卫材R&D管理有限公司 软胶囊剂
WO2006103657A2 (fr) * 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. Composition solide de distribution intra-buccale d'insuline
EP1952803A1 (fr) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Composition pharmaceutique solide contenant des phospholipides hydrogénés
JP5196833B2 (ja) * 2007-04-07 2013-05-15 ヤヱガキ醗酵技研株式会社 機能性食品素材とその製造方法
WO2009071295A1 (fr) * 2007-12-05 2009-06-11 Dsm Ip Assets B.V. Formulation pulvérulente d'un ingrédient actif liposoluble
US8603568B2 (en) 2010-01-15 2013-12-10 Kemin Industries, Inc. Hydrolyzed lecithin product to improve digestibility
WO2012070031A1 (fr) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg Matrice polymère de nanoparticules de polymère-lipide en tant que forme pharmaceutique dosifiée
US10722458B2 (en) 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
GB201415381D0 (en) * 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
EP3212169B1 (fr) * 2014-10-31 2021-01-13 Bend Research, Inc. Procédé de formation de domaines actifs dispersés dans une matrice
CN108366978B (zh) * 2015-10-09 2021-06-01 三荣源有限公司 含有多酚的固体组合物
CN114831128A (zh) * 2022-04-06 2022-08-02 安徽华辰检测技术研究院有限公司 一种含有苯醚甲环唑和嘧菌酯的农药制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CN1065415C (zh) * 1993-02-05 2001-05-09 花王株式会社 蛋白质和类脂复合体用于改善味觉的用途
JPH06245719A (ja) * 1993-02-19 1994-09-06 Nippon Oil & Fats Co Ltd 粉末乳化剤および製造方法
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
GB2326337A (en) * 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055820A1 (fr) 2019-09-20 2021-03-25 Novartis Ag Acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et sa formulation de sels
WO2022195545A1 (fr) 2021-03-18 2022-09-22 Novartis Ag Nouvelles formulations pharmaceutiques

Also Published As

Publication number Publication date
WO2000033817A1 (fr) 2000-06-15
JP2002532389A (ja) 2002-10-02
EP1137402A1 (fr) 2001-10-04
AU1787800A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
CA2352178A1 (fr) Compositions de phospholipides
Yuksel et al. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: in vitro and in vivo evaluations
JP4969104B2 (ja) 多孔質セルロース凝集体及びその成型体組成物
Huang et al. A novel plug-controlled colon-specific pulsatile capsule with tablet of curcumin-loaded SMEDDS
KR101824831B1 (ko) 신규 멜록시캄 제제
CN102256597A (zh) 制备含有不溶性药物的纳米颗粒的粉末的方法、由此制备的粉末以及含有该粉末的药物组合物
SG177281A1 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
JP2020531424A (ja) メロキシカムを含有する注射用医薬組成物、およびその製造方法
CN102014910A (zh) 在无食物条件下施用齐拉西酮的方法、剂型和试剂盒
US6376481B2 (en) Sterol esters in tableted solid dosage forms
AU2010261512A1 (en) Nanoparticulate Candesartan Cilexetil compositions, process for the preparation thereof and pharmaceutical compositions containing them
AU2010261511A1 (en) Nanoparticulate Olmesartan Medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
CN102892411A (zh) 含有合成的低聚糖的药物口服剂型
CN104188926A (zh) 化学物质的胶束纳米颗粒
AU2008300030A1 (en) Pharmaceutical compositions for oral use for treating patients affected by obesity
DE60309356T2 (de) Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich
CN110381945A (zh) 口服给予的镓（iii）配合物的组合物
CN103040764A (zh) 一种盐酸平阳霉素脂质体注射剂
CN103142518B (zh) 一种阿格列汀脂质体固体制剂及其制备方法和应用
US20050215455A1 (en) Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them
US20230165804A1 (en) Solid lipid nanoparticle for intracellular release of active substances and method for production the same
AU2004324858A1 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20070292503A1 (en) Oral pharmaceutical composition of poorly water-soluble active substance
KHAZIM et al. Formulation of probiotics loaded granules of 5-Amino salicylic acid for colon targeting drug delivery system
Jain et al. Dual Component Tablets for the Treatment of Gastroesophageal Reflux Disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead